Fertility -focus (1)

With its second successful SyndicateRoom raise overfunded to £360,250, Fertility Focus will get its next generation product into the market and continue its excellent record of helping women conceive and understand their bodies’ reproductive patterns.

The Story

Fertility Focus was formed in 2005 to help couples get pregnant more quickly and at a lower cost. It’s estimated that 24 million women worldwide seek online advice for fertility problems, and 30% of all women have fertility issues that go unnoticed by doctors. So Fertility Focus created OvuSense: a fertility monitor to help these women manage their cycles and detect if they have ovulatory issues. Unlike its competitors, OvuSense works in real time, and is capable of predicting ovulation with 89% accuracy and confirming it with 99% accuracy.

IMG_0714.21-1024x 682 Where are they now?

OvuSense is already approved and on the market in Europe and the USA. It has six patents and five clinical publications. Furthermore, the company has now secured enough funding outside of SyndicateRoom to start developing its new mobile app. The app will allow the product’s sensor to talk directly to the user’s phone, so the large analysis component will no longer be needed. In turn, this will allow the upfront cost for the user to be reduced from £250 to £30, hopefully leading to much higher sales volumes. Progress with the hardware side of the project is almost done, and the new 3rd generation OvuSense will be in the market by Christmas.

See current opportunities

Apta Biosciences Ltd

EIS
Pharmaceuticals & Biotechnology
Game-changing technology for multi-billion dollar life sciences research, diagnostics and therapeutics markets. Read about Apta Biosciences raise here.

Active

Trading status

£9,944

Average investment

£964,550

Total raised

Weedingtech

EIS
Technology, Hardware & Equipment
Manufacturers of Europe’s leading herbicide-free weed control systems, Weedingtech raised funds on SyndicateRoom. Read about the raise here.

Active

Trading status

£19,543

Average investment

£801,257

Total raised

The Diabetic Boot Company

EIS
Medtech
Developing a unique wound healing device, focussed on saving diabetics from lower limb amputations. The global market for this product exceeds $1 billion.

Active

Trading status

£21,784

Average investment

£1,764,494

Total raised

Bactest - Round 2

EIS
Pharmaceuticals & Biotechnology
Bactest develops and sells products based on its propriety technology platform that turns microbial activity into data.

Dissolved

Trading status

£12,070

Average investment

£301,760

Total raised

Enval

EIS
Engineering & Manufacturing
Enval’s microwave induced pyrolysis process is a world-first method for recycling laminated packaging, and is now operational at full commercial-scale.

Active

Trading status

£14,655

Average investment

£981,870

Total raised

CommonTime Limited

EIS
Software & Computer Services
A new way to make, mobilise and manage business mobile applications. 2011 Rolls-Royce Innovative Business of the Year with £2m in revenue in 2014.

Active

Trading status

£26,611

Average investment

£745,099

Total raised